Product support

E-mail: support@scyfix.org

Europe, Middle East, Turkey, Africa and web shop:
Stefan Bengtsson
Prospectus AB
Sockenvägen 477
SE-12233 Enskede
Sweden
Tel +46 705 60 33 60
E-mail: sbengtsson@scyfix.com

Belgium, the Netherlands and Luxemburg:
 Robert Nolens
Low Vision Centrum
Dorpsstraat 18
B-3500 Hasselt
Belgium
Phone: +32 11 22 76 96
Fax: +32 11 24 32 54
E-mail: robert.nolens@pandora.be

Corporate information, USA:
 Thomas W. Harold
CEO
ScyFIX
570 West 78th Street
#2001
Chanhassen, MN 55317
USA
Phone: 612-964-6500
Fax: 952-975-0616
Europe Mobile: +46 733 50 10 91
Email: tharold@scyfix.com

India:
India Distribution Partner:
 Sanjai Ojha
Intas Pharmaceuticals Ltd
Chinubhai Centre, Off. Nehru Bridge, Ashram Road,
Ahmedabad - 380009. Gujarat. India.
Phone: +91-79-2657 6655
Fax : +91-79-2657 8862
Email: info@intaspharma.com Email: sanjai_ojha@intaspharma.com

Malaysia:
 Intelgen Pte Ltd

Money Ngoh
Business Manager
Mobile: 02-97343436
Email: freedoms@singnet.com.sg

Abby Soon
Business Manager
Mobile: 012-3861909
Email: abbysoon@myjaring.net 14-1, Jalan SS19/1G
47500 Subang Jaya
Selangor
Malaysia
Phone: +603-5631 0933
Fax: +603-5638 6990
Mobile: 0917 539-2258

Middle East and Africa:
 Dr Tarek Badawy
Low Vision Consultant
42 Dr. Ezat Salama st., from Abbas El Akkad street
11371 Nasr city , Cairo
Egypt
Phone: +002 010 1443377
Fax: +002 02 7946896
E-mail: tbadawy@vodafonemail.net

 
     

Breaking News! The ScyFIX 700 MCN Therapy is the only patented Micro Current Neuromodulation (MCN) device approved in Europe for the treatment of Retinitis Pigmentosa. Compelling Clinical Results: Retinitis Pigmentosa (RETINITIS PIGMENTOSA) and our Dry Age-Related Macular Degeneration (“ARMD”) are degenerative diseases, and improvement in visual fields, visual acuity, or contrast sensitivity is not expected. Data through twenty-four months suggests that MCN therapy is clinically effective. The data reflects that MCN therapy has not only slowed down the progression of disease symptoms as intended, but has in many cases halted, and in some cases reversed the progression of the diseases.
Patients are now using mobile phones, reading newspapers, seeing faces of family members and threading needles, none of these day to day activities were possible for these patients before using the ScyFIX MCN device. Similar compelling results have been achieved in our Dry Age-Related Macular Degeneration (“ARMD”) trial as well.